Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating)’s stock price traded up 8.4% during mid-day trading on Monday . The stock traded as high as $8.32 and last traded at $8.23. 443,238 shares changed hands during trading, a decline of 75% from the average session volume of 1,793,685 shares. The stock had previously closed at $7.59.

Several equities research analysts have issued reports on the company. StockNews.com assumed coverage on Editas Medicine in a research report on Thursday, March 16th. They set a “sell” rating on the stock. Royal Bank of Canada dropped their target price on Editas Medicine from $14.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 23rd. Credit Suisse Group increased their target price on Editas Medicine from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Thursday, February 23rd. Wells Fargo & Company dropped their target price on Editas Medicine from $36.00 to $30.00 in a research report on Thursday, February 23rd. Finally, Cantor Fitzgerald started coverage on Editas Medicine in a research report on Tuesday, January 31st. They issued an “overweight” rating and a $15.00 price objective on the stock. Three analysts have rated the stock with a sell rating, seven have assigned  a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $15.33.

The stock has a 50 day moving average of $8.35 and a 200 day moving average of $9.69.

Editas Medicine (NASDAQ:EDIT – Get Rating) last announced its quarterly earnings data on Wednesday, February 22nd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.04). Editas Medicine had a negative net margin of 1,118.32% and a negative return on equity of 50.28%. The company had revenue of $6.54 million for the quarter, compared to the consensus estimate of $3.76 million. During the same period last year, the business posted ($0.61) earnings per share. The firm’s quarterly revenue was down 47.6% compared to the same quarter last year.  On average, equities analysts forecast that  Editas Medicine, Inc. will post -3.04 EPS for the current year.

In other news, CFO Michelle Robertson sold 4,287 shares of the firm’s stock in a transaction dated Monday, February 13th. The stock was sold at an average price of $9.67, for a total transaction of $41,455.29. Following the transaction, the chief financial officer now directly owns 76,243 shares of the company’s stock, valued at $737,269.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Mark S. Shearman sold 2,790 shares of the firm’s stock in a transaction dated Monday, February 13th. The stock was sold at an average price of $9.67, for a total transaction of $26,979.30. Following the transaction, the executive vice president now directly owns 65,559 shares of the company’s stock, valued at $633,955.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Michelle Robertson sold 4,287 shares of the stock in a transaction dated Monday, February 13th. The stock was sold at an average price of $9.67, for a total transaction of $41,455.29. Following the sale, the chief financial officer now owns 76,243 shares of the company’s stock, valued at $737,269.81. The disclosure for this sale can be found here. Over the last three months, insiders have sold 7,708 shares of company stock valued at $74,809. 1.30% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of the company. Lazard Asset Management LLC boosted its holdings in shares of  Editas Medicine by 10.1% during the third quarter. Lazard Asset Management LLC now owns 9,552 shares of the company’s stock worth $116,000 after purchasing an additional 873 shares during the period.  Congress Asset Management Co. MA lifted its holdings in  Editas Medicine by 1.3% in the third quarter. Congress Asset Management Co. MA now owns 80,069 shares of the company’s stock worth $980,000 after buying an additional 1,004 shares during the period.  Bank of New York Mellon Corp lifted its holdings in  Editas Medicine by 0.4% in the first quarter. Bank of New York Mellon Corp now owns 288,878 shares of the company’s stock worth $5,494,000 after buying an additional 1,060 shares during the period.  Cambridge Investment Research Advisors Inc. lifted its holdings in  Editas Medicine by 1.8% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 66,471 shares of the company’s stock worth $814,000 after buying an additional 1,159 shares during the period.  Finally, ProShare Advisors LLC lifted its holdings in  Editas Medicine by 8.8% in the fourth quarter. ProShare Advisors LLC now owns 14,577 shares of the company’s stock worth $129,000 after buying an additional 1,180 shares during the period. 69.67% of the stock is currently owned by hedge funds and other institutional investors.

Editas Medicine, Inc engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J.

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.